Home › Trials › NCT07101497
Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 12 and up

BN104 maintenance after allogeneic stem cell transplant for acute leukemia

Official title: Phase 2 Trial of Menin Inhibitor BN104 as Post Hematopoietic Stem Cell Transplantation Maintenance in Patients With Acute Leukemia

Run by The First Affiliated Hospital of Soochow University · NCT07101497 · Data updated 2026-11-12

This trial tests whether taking the oral menin inhibitor BN104 can reduce relapse in people with acute leukemia who have specific genetic changes and are 1–6 months after an allogeneic stem cell transplant.

Quick facts

PhasePhase 2
Study typeInterventional
Ages12 Years and up
SexAll
Enrollment60 (estimated)
SponsorThe First Affiliated Hospital of Soochow University
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Suzhou, Jiangsu)
StatusRecruiting
StartedAugust 1, 2025
Main results expectedDecember 31, 2027
Study endsDecember 30, 2029
Registry record updatedAugust 3, 2025
Trial IDNCT07101497 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are people aged 12 or older (≥35 kg) with AML, ALL, or ambiguous acute leukemia in complete hematologic remission who harbor menin‑dependent alterations (for example KMT2A rearrangements, NUP98 rearrangements, or NPM1 mutation without FLT3 co‑mutation), are 30–180 days post allogeneic HSCT with full donor chimerism and adequate blood counts.

Probably not a fit

Patients without the specified menin‑dependent genetic alterations, those not in complete remission, those who are too early (<30 days) or too late (>180 days) after transplant, or those without adequate blood count recovery are unlikely to be eligible or to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open‑label, single‑arm Phase 2 trial giving BN104 orally at 100–200 mg twice daily in 28‑day cycles for up to 24–36 cycles to people with acute myeloid, lymphoblastic, or ambiguous leukemia who harbor menin‑dependent genetic alterations. Eligible participants are screened and begin therapy 30–180 days after allogeneic hematopoietic stem cell transplantation, must be in complete hematologic remission with recovered counts and full donor chimerism. The primary endpoint is the two‑year relapse‑free survival rate from enrollment; secondary endpoints include overall survival, event‑free survival, cumulative relapse incidence, non‑relapse mortality, GVHD incidence, and safety. The study aims to determine whether BN104 can extend remission duration when used as post‑transplant maintenance in this high‑risk molecular subgroup.

Why it matters

Potential benefit: If successful, BN104 could lower the chance of relapse and extend relapse‑free survival after allo‑HSCT for patients with menin‑dependent genetic alterations.

How similar studies have gone: Other menin inhibitors have shown promising remission activity in relapsed or refractory cases with KMT2A fusions, but using BN104 specifically as post‑HSCT maintenance is a novel approach that has not been proven yet.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or female patients.
* Adult and adolescent patients aged ≥12 years who must weight ≥35 kg.
* Diagnosed with acute myeloid leuekmia, acute lymphoblastic leukemia or ambiguous acute leukemia according to the World Health Organization classification of hematologic neoplams (WHO 2022).
* Intermediate or high risk accroding to the ELN risk stratification.
* Harboring one of the following genetic aberrations: a. somatic NPM1 mutation (without FLT3-ITD/TKD co-mutations); b. KMT2A rearrangement/KMT2A-PTD; c. NUP98 rearrangement; d. other genetic alterations dependent on menin-KMT2A.
* Received allogenic hematopoietic stem cell transplantation within 30-180 days at the initiation of BN104 maintenance therapy.
* Achieved full donor chimerism and hematologic recovery, with acute neuthrophil count (ANC) ≥1.0×10⁹/L, platelets ≥75×10⁹/L (no red blood cells /platelets transfusion within 7 days, no G-CSF or GM-CSF within 72 hours).
* Complete hematological remission (CHR) after first allo-SCT. CHR must be confirmed by bone marrow analysis within 14 days before entering the study (CHR criteria are: "\< 5% marrow blasts, no peripheral blasts, blood platelet count \> 75×10⁹/L, WBC count \> 3.5 G/L, ANC ≥ 1.0×10⁹/L).
* No extramedullary leukemia.
* Eastern Cooperative Oncology Group (ECOG) performance status score 0-2.
* Adequate organ function
* Provided informed consent by all patients and the guardians ( aged 12-17 years).
* Written informed consent.
* ECOG ≥ 2.

Exclusion Criteria:

* Complicated with active and uncontrolled infections.
* Activation of virus, (e.g., CMV viremia with CMV DNA copies \> 400 copies/ml, EBV viremia with EBV DNA copies \> 400 copies/ml, and proof of activation of adenovirus and Human Parvovirus B19 ).
* Activation of hepatitis B, hepatitis C, or human immunodeficiency virus.
* Cardiac disease as followings: a. inherited long QT syndrome. b. Congestive heart failure with NYHA ≥ grade 2.
* ≥ grade 2 acute GVHD or ≥ grade 3 chronic GVHD which requiring systemic therapy.
* Have received other maintenance therapies (e.g., hypomethylating agents, targetd drugs such as Bcl-2 inhibitors, FLT3 inhibitors, IDH1/2 inhibitors, interferon, interleukin-2, donor lymphocyte infusion and chemotherapy).
* History of other malignancies which needed systemic treatment (excluding those in stable remission without maintenance therapy).
* Any gastrointestinal condition that may interfere with oral drug intake or absorption (e.g., dysphagia, gastroparesis, uncontrolled chronic diarrhea, intestinal graft versus host disease.
* Pregnancy, breastfeeding
* Hypersensitivity to BN104.

Where it's running

  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Menin Inhibitors 2Post Hematopoietic Stem Cell Transplantation 2Maintenance Therapy 7Acute Leukemia 72KMT2A Rearrangement 3NPM1 Mutation 6NUP98 Gene Rearrangement 2The First Affiliated Hospital of Soochow University 90
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.